Background. Elvitegravir (EVG)/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is approved for treatment of HIV-1 in children weighing ≥25 kg based on a Gilead sponsored study of safety, pharmacokinetics (PK), and antiviral activity among 23 virologically suppressed (VS) children 6-<12 years old who switched from a stable antiretroviral (ARV) regimen to E/C/F/TAF. All subjects were perinatally infected with HIV. Though all subjects maintained HIV viral load < 50 copies/mL, a decrease in mean CD4+ cell count (CD4ct) occurred at Week 2 and persisted to Week 24 (Table 1) . Methods. We explored possible reasons for CD4ct declines including change in overall leukocyte and absolute lymphocyte count (ALC), relationship between CD4ct and PK of each drug in E/C/F/TAF, and trends in subject-level CD4ct. We reviewed prior ARV trials and literature to look for drug class effects.
Results. Decreased CD4cts were not explained by declines in total leukocyte counts or ALC. There was no association between CD4ct and area under the curve (AUC) of any of the four drugs. Mean CD4ct decline was not driven by a few outliers; CD4ct declined in 21/23 subjects. Prior ARV trials of VS adults and children, including EVG-containing regimens, show no notable sustained decline in CD4ct. Pediatric studies of other integrase inhibitors (INSTI) in this age group did not have comparable VS subjects. The literature describes structural similarity between human recombinant activation gene (RAG)1/2 and HIV integrase. RAG inhibition by INSTIs could potentially interfere with B and T cell development. EVG exposure in mice at supra-therapeutic concentrations, caused significant reductions in mature B lymphocytes. The relevance of this finding to humans is unclear.
Conclusion. Decreased CD4ct is a unique finding in this pediatric study of E/C/F/TAF and the etiology remains unclear. Inhibition of RAG1/2 by EVG may play a role, but further research is needed. No subjects had nadir CD4ct < 350 and no opportunistic infections were reported. However, CD4 declines are included in E/C/F/TAF labeling to alert providers of this potential risk.
Disclosures. Methods. An anonymous email-based survey was sent to 396 youth providers in Utah during an 8-week span in 2017. 102 (26%) responded and analysis was limited to 83 (21%) providers who reported caring for patients aged 15-24.
Results. The median age of providers was 35.5; median years out of residency 8.5; most were female (54%); self-identified as Caucasian (86%); attending level physicians (70%) and many (61%) practiced in urban settings. Over half identified as moderately, very, or extremely comfortable screening for HIV. Approximately 75% were familiar with CDC HIV testing guidelines. However, only 16% report always or often testing youth for HIV. Providers were more likely to screen for HIV in older patients; 19% always or often screening patients age 17-24 and 10% of patients age 13-16. Factors that increased the likelihood of offering an HIV test included: patient request, men who report sex with men, prior STI or a history of injection drug use (Figure 1 ). Common reasons for rarely or never offering testing included: belief the patient panel is not sexually active, low prevalence of HIV and provider discomfort in discussing sexual behaviors ( Figure 2 ). Less than one-third of providers reported familiarity with the CDC's PrEP guidelines, but most (91%) expressed interest in more information. Provider discomfort in offering PrEP was highest in the younger patients ( Figure 3 ). The same factors that increased the likelihood of testing for HIV held true for prescribing PrEP.
Conclusion. In Utah, the majority of providers are familiar with CDC HIV testing guidelines; however, testing remains low. This may be due to misconceptions around HIV risk and provider comfort. This is a missed opportunity for early detection of HIV in a population with known high rates of other STIs. Youth providers are not familiar with PrEP but they would like further education.
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No reported disclosures. Background. Seasonal influenza infection is associated with secondary bacterial complications involving the upper and lower respiratory tract. However, the association of influenza infection with secondary severe or complicated head and neck infections is not appreciated.
Severe Head and Neck Infections Following Influenza Virus Infection in Children
Methods. We performed a retrospective review of pediatric patients hospitalized at Texas Children's Hospital with bacterial head or neck infections following influenza infection from October 2017 to March 2018. We queried the infectious diseases consult database using the search terms: orbital cellulitis, mastoiditis, retropharyngeal abscess, S698 • OFID 2018:5 (Suppl 1
Results. We identified 44 patients with head or neck infections, of which 6 patients met inclusion criteria (table) . The male-to-female ratio was 5:1 and the median age was 11.6 years (range 1.7-13.9 years). Most patients were diagnosed with influenza during a period of high influenza activity and the median time from influenza diagnosis to hospital admission was 4.5 days (range 1-6 days). One patient had received seasonal influenza vaccination. Patients had a wide range of infections, including orbital cellulitis (3), retropharyngeal abscess (2), and 1 of each of the following: Lemierre's syndrome, peritonsillar abscess, Pott's puffy tumor, and subdural empyema; 4 also had sinusitis. A causative pathogen was established in four cases: methicillin-resistant Staphylococcus aureus, Streptococcus anginosus group, S. pyogenes, and S. intermedius. The median duration of hospitalization was 22 days (range 5-35 days) and treatment duration ranged from 3.5 to 6 weeks. All patients completed antibiotic treatment successfully and had favorable outcomes.
Conclusion. We suggest that complicated bacterial head and neck infections may represent an under recognized co-infection or secondary complication of infection with influenza virus, further stressing the importance of prevention and treatment of influenza infection. Background. The CDC has reported that seasonal influenza in 2017-2018 has been one of the worst on record, with hospitalization rates among the highest recorded, especially among younger age groups (age 50-65, hospitalization rate of 63.1 per 100,000 people compared with 35.1 in last severe season, 2015-2016) . Understanding how antiviral use affects rates and severity of complications is important to inform treatment decisions. This study used real-world US claims data for 3 flu seasons (2014) (2015) (2016) to understand the frequency of flu complications and how intervention with antivirals may affect their occurrence.
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Antiviral Use Is Associated With a Decrease in Rate of
Methods. This was a retrospective cohort study using US commercial claims data from the 2014-2016 flu seasons. Patients with a diagnosis code for flu were identified and required to have continuous coverage for at least 365 days before and 91 days after diagnosis. Patients who were prescribed antivirals within 48 hours of the first flu-related encounter during the flu season were identified and propensity score matched to a comparative cohort without antiviral use within 48 hours but comparable baseline health resource utilization (HRU) and comorbidities. All-cause and respiratory-related HRU and costs in the 30 and 91 days after flu diagnosis were analyzed and compared.
Results. A total of 989,530 cases of influenza were identified over 3 flu seasons, with 60.2 percent receiving antiviral therapy (Table 1 ). In the matched sample, greater HRU and costs was identified in the cohort that did not receive antiviral therapy, with 15% vs. 10.4% (P < 0.001) visiting the ER, and 2.8% vs. 0.9% (P < 0.001) being admitted for inpatient care within the first month (Table 2) . Similarly, greater HRU was also seen in respiratory-related HRU and costs in the cohorts that did not receive antiviral therapy. Findings were similar in unmatched cohorts.
Conclusion. In data for the last 3 available flu seasons, flu patients treated with antivirals had less complications, healthcare resource utilization and overall costs than those who did not receive antiviral treatment. Limitations with this kind of study restrict the conclusions that can be made from this analysis, however suggest that treating flu can improve outcomes and resource utilization beyond symptom resolution. Background. Influenza is a common cause of morbidity and mortality in children. This was a retrospective study of hospitalized children with influenza at KKH admitted from January 2013 to December 2014 to compare the type of complications by age and underlying medical conditions.
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Methods. Influenza patients were identified by a positive polymerase chain reaction (PCR) or immunoflourescence antigen from nasopharyngeal swabs. Patients were grouped into neurologic, respiratory, other and no complication. Multinomial regression was used to compare age and complications with underlying disease.
Results. There were a total of 1,272 patients with a median age of 37 months (IQR 13-76 months). Influenza A constituted 76.3% with serotype H3N2 (54.5%), H1N1 (18.2%), unknown (5.4%). Influenza B constituted 22.9% with serotypes: Yamagata (16.3%), Victoria (5.7%). Only 4 patients (0.3%) had sequelae or death. 28% of influenza admissions had complications. The most common being neurologic 44% (n = 156) followed by respiratory 31% (n = 110). The most common clinical complications were: febrile seizure 34.1%, bronchitis/bronchiolitis 9.9%, pneumonia 7.3%. There was a significant difference between complications by male gender (P = 0.001), community acquisition (P = 0.007), influenza type, other positive viruses, comorbidity, asthma/ lung disease, neurologic disease, history of seizures, ICU/High Dependency admissions (all P ≤ 0.001), developmental delay (P = 0.002), Kawasaki disease on aspirin (P = 0.026), gastro-esophageal reflux (P = 0.034) and prescription of oseltamivir (P = 0.003). Neurologic complications occurred especially in the 2-< 5 year age group (37.2%), respiratory complications in the 6-23 month age group (39.1%). Age ≥5 year was more likely to have neurologic complication if they had a history of seizures (OR 14.2, P < 0.001). Age ≥2 years was more likely to have respiratory complications if they had asthma/ lung disease (OR 3.5, P < 0.001).
Conclusion. Although influenza mortality was low, 28% of influenza admissions in children had significant complications. Children with underlying medical problems should routinely receive influenza vaccinations to avoid complicated influenza illness.
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